Short answer
ImmunityBio, Inc. (IBRX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $49M (up 52.3% year over year) with net income of −$185M.
Q3 2026 key financials · XBRL
- Revenue
- $49M
- +52.3% YoY · −4.7% QoQ
- Net income
- −$185M
- −174.4% YoY · +19.9% QoQ
- Operating margin
- -159.7%
- EPS (diluted)
- −$0.17
- −183.3% YoY · +19.0% QoQ
Source: XBRL data from the ImmunityBio, Inc. (IBRX) Q3 2026 10-Q on SEC EDGAR. USD.
ImmunityBio, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $48.8M, up from $32.1M YoY, driven by ANKTIVA product revenue of $48.7M, up 53%
- Operating loss $78.0M vs $55.6M YoY, operating margin (159.7%) vs (173.5%)
- ANKTIVA best-performing product, revenue increased $17.0M; no segment disclosures
- Cash, equivalents and marketable securities $334.3M vs $242.8M at December 31, 2025
- Outlook: R&D expenses expected to increase significantly; substantial additional funding required, with going-concern doubt absent support
Risk Factors
- Newly expanded ANKTIVA indication: FDA approval on October 14, 2026 for BCG-unresponsive NMIBC with high-grade papillary-only tumors
- Regulatory compliance: QUILT-3.032 completion and annual FDA reporting required through 2029
- Near-term market risk: ongoing TICE BCG shortage constraining ANKTIVA uptake and clinical-trial execution
- Liquidity risk: $334.3 million cash and securities versus $480.0 million convertible note and over $426.3 million RIPA liability
- RIPA exposure: revenue-interest payments ranging from 5.625% to 12.50% of worldwide net sales excluding China
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ImmunityBio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.